- Home
- WF vs NBIX Comparison
WF vs NBIX Comparison
Compare WF & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | NBIX |
|---|---|---|
| Founded | 1899 | 1992 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 14.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | WF | NBIX |
|---|---|---|
| Price | $58.33 | $155.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $173.79 |
| AVG Volume (30 Days) | 56.0K | ★ 969.9K |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | ★ 20.51 | 12.44 |
| EPS | 2.97 | ★ 4.19 |
| Revenue | ★ $8,054,512,650.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $4.26 | $18.01 |
| P/E Ratio | ★ $6.47 | $37.10 |
| Revenue Growth | ★ 23.56 | 19.61 |
| 52 Week Low | $29.44 | $84.23 |
| 52 Week High | $59.88 | $157.67 |
Technical Indicators
Market Signals| Indicator | WF | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 64.81 |
| Support Level | $57.48 | $150.26 |
| Resistance Level | $59.88 | $154.35 |
| Average True Range (ATR) | 1.39 | 4.16 |
| MACD | 0.50 | 1.07 |
| Stochastic Oscillator | 86.01 | 93.25 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.